Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-m9kch Total loading time: 0 Render date: 2024-06-06T17:03:09.862Z Has data issue: false hasContentIssue false

AGOMELATINE

Published online by Cambridge University Press:  03 April 2024

Stephen M. Stahl
Affiliation:
University of California, San Diego and Riverside
Get access

Summary

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Prescriber's Guide
Stahl's Essential Psychopharmacology
, pp. 5 - 10
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

DeBodinat, C, Guardiola-Lemaitre, B, Mocaer, E, et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization, and development. Nat Rev Drug Discov 2010;9:628–42.Google Scholar
Goodwin, GM, Emsley, R, Rembry, S, Rouillon, F. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:1128–37.CrossRefGoogle ScholarPubMed
Kennedy, SH, Avedisova, A, Belaïdi, C, Picarel-Blanchot, F, de Bodinat, C. Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months. Neuropsychopharmacol 2016;26(2):378–89.Google ScholarPubMed
Khoo, AL, Zhou, HJ, Teng, M, et al. Network meta-analysis and cost-effectiveness analysis of new generation antidepressants. CNS Drugs 2015;29(8):695712.CrossRefGoogle ScholarPubMed
Martinotti, G, Sepede, G, Gambi, F, et al. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J Clin Psychopharmacol 2012;32(4):487–91.CrossRefGoogle ScholarPubMed
Racagni, G, Riva, MA, Molteni, R, et al. Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors. World J Biol Psychiatry 2011;12(8):574–87.CrossRefGoogle ScholarPubMed
Stahl, SM. Mechanism of action of agomelatine: a novel antidepressant exploiting synergy between monoaminergic and melatonergic properties. CNS Spectr 2014;19:207–12CrossRefGoogle ScholarPubMed
Stahl, SM, Fava, M, Trivedi, M, et al. Agomelatine in the treatment of major depressive disorder. An 8 week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry 2010;71(5):616–26.CrossRefGoogle ScholarPubMed
Stein, DJ, Picarel-Blanchot, F, Kennedy, SH. Efficacy of the novel antidepressant agomelatine on anxiety symptoms in major depression. Hum Psychopharmacol 2013;28(2):1519.CrossRefGoogle ScholarPubMed
Taylor, D, Sparshatt, A, Varma, S, Olofinjana, O. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ 2014;348:g2496.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • AGOMELATINE
  • Stephen M. Stahl, University of California, San Diego and Riverside
  • Book: Prescriber's Guide
  • Online publication: 03 April 2024
  • Chapter DOI: https://doi.org/10.1017/9781009464772.002
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • AGOMELATINE
  • Stephen M. Stahl, University of California, San Diego and Riverside
  • Book: Prescriber's Guide
  • Online publication: 03 April 2024
  • Chapter DOI: https://doi.org/10.1017/9781009464772.002
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • AGOMELATINE
  • Stephen M. Stahl, University of California, San Diego and Riverside
  • Book: Prescriber's Guide
  • Online publication: 03 April 2024
  • Chapter DOI: https://doi.org/10.1017/9781009464772.002
Available formats
×